Novartis AG (NVSEF) revenue by segment
NVSEFOTCPharmaceutical PreparationsFiscal year ends December 31Also trades as NVS
$146.46+2.56 (+1.78%)
Close on Oct 19, 2026Market cap $279.46BP/E 20.5Yield –
Novartis AG revenue by segment
By business segment
| Operating income | Q2 23 | Q4 22 | Q2 22 | Q4 21 | Q2 21 | Q4 20 | Q2 20 | Q4 19 | Q2 19 | Q4 18 | Q2 18 | Q4 17 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Innovative Medicines | $3.00B | – | $2.21B | – | $3.18B | – | $2.03B | – | $2.56B | – | $2.25B | – | +35.9% |
| Sandoz | $212.00M | – | $357.00M | – | $462.00M | – | $321.00M | – | $282.00M | – | $328.00M | – | -40.6% |
| Corporate | -$291.00M | – | -$335.00M | – | -$160.00M | – | -$2.00M | – | -$183.00M | – | -$149.00M | – | -13.1% |
| Alcon [member] | – | – | – | – | – | – | – | – | – | – | $65.00M | – | – |
By product or service
By region
From the segment and revenue-disaggregation notes of Novartis's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.
See a number that looks wrong?